MedPath

Genmab

Genmab logo
🇩🇰Denmark
Ownership
Public
Employees
2.2K
Market Cap
$17.7B
Website
http://www.genmab.com

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Phase 2
Completed
Conditions
Cutaneous T-Cell Lymphoma
Interventions
First Posted Date
2003-10-15
Last Posted Date
2023-04-28
Lead Sponsor
Genmab
Target Recruit Count
22
Registration Number
NCT00071084
Locations
🇺🇸

Stanford University Med Ctr., Dept of Dermatology, Stanford, California, United States

🇺🇸

University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

Phase 2
Terminated
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
First Posted Date
2002-08-01
Last Posted Date
2023-04-28
Lead Sponsor
Genmab
Target Recruit Count
83
Registration Number
NCT00042406
Locations
🇺🇸

Rheumatology Associates, Montgomery, Alabama, United States

🇺🇸

Pro Health Partners, Inc., Long Beach, California, United States

🇺🇸

Rheumatology & Internal Medicine, Boling Clinical Trials, Rancho Cucamonga, California, United States

and more 49 locations
© Copyright 2025. All Rights Reserved by MedPath